Nonhuman Primate Induced Pluripotent Stem Cells in Regenerative Medicine by Wu, Yuehong et al.
Hindawi Publishing Corporation
Stem Cells International
Volume 2012, Article ID 767195, 7 pages
doi:10.1155/2012/767195
Review Article
NonhumanPrimate InducedPluripotentStemCellsin
Regenerative Medicine
Yuehong Wu,1,2,3 AnujaMishra,1,2 Zhifang Qiu,1,2 Steven Farnsworth,1,2
Suzette D. Tardif,1,2 and PeterJ. Hornsby1,2
1Department of Physiology and Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center,
15355 Lambda Drive, San Antonio, TX 78245, USA
2Geriatric Research Education and Clinical Center, South Texas Veterans Healthcare System, San Antonio, TX 78229, USA
3Key Laboratory of Ministry of Education for Protection and Utilization of Special Biological Resources in Western China,
and College of Life Science, Ningxia University, Yinchuan, Ningxia 750021, China
Correspondence should be addressed to Peter J. Hornsby, hornsby@uthscsa.edu
Received 16 September 2011; Accepted 27 January 2012
Academic Editor: Rajarshi Pal
Copyright © 2012 Yuehong Wu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Among the various species from which induced pluripotent stem cells have been derived, nonhuman primates (NHPs) have a
unique role as preclinical models. Their relatedness to humans and similar physiology, including central nervous system, make
them ideal for translational studies. We review here the progress made in deriving and characterizing iPS cell lines from diﬀerent
NHP species. We focus on iPS cell lines from the marmoset, a small NHP in which several human disease states can be modeled.
The marmoset can serve as a model for the implementation of patient-speciﬁc autologous cell therapy in regenerative medicine.
1. Induced Pluripotent Stem Cells in
Regenerative Medicine
The aims of regenerative medicine are to restore healthy
function to organs damaged by disease or aging. A major
issueisthesourceofcellstobeusedinregenerativemedicine.
Itisoftenthoughttobedesirabletousecellsderivedfromthe
patient himself/herself, because this is hypothesized to avoid
the need to administer drugs to suppress immune rejection
of the transplanted cells. The possibility of using patient-
speciﬁc cells in regenerative medicine was greatly expanded
by the discovery of induced pluripotent stem cells (iPS cells)
[1, 2]. iPS cells can be derived from any somatic cell, but
have the properties of embryonic stem cells. Like embryonic
cells, they can be used to generate any cell of the body that
may be needed in regenerative medicine. It is widely thought
that a form of autologous cell therapy will be possible, in
which iPS cells would be derived from the patient’s cells, in
order to provide a source for cells that could be transplanted
back to the patient to restore function to the heart, central
nervous system, hematopoietic system, or other organs that
are aﬀected by disease or aging. The present experiments
concern the development of nonhuman primate models for
autologous cell therapy based on iPS cells.
2.Autologous versusAllogeneic
CellsinCell-BasedTherapies
Any consideration of the implementation of regenerative
medicine for human subjects must assess the source of the
cells used in the therapy [3, 4]. Following the discovery
of iPS cells, it was almost immediately realized that this
discovery opened the way to autologous cell therapy. A
review in 2007 stated: “If this method can be translated
to humans, patient-speciﬁc stem cells could be made
without the use of donated eggs or embryos” [5]. It is
assumed that if the cells are accepted as “self” then they
would represent the best possible functional outcome of
a transplant: cells that function in their natural environ-
ment, without eliciting chronic immune or inﬂammatory
reactions, and without the problems that would result2 Stem Cells International
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Figure 1: The marmoset as a preclinical model for patient-speciﬁc
iPS cells in regenerative medicine. This scheme outlines progress
to date and future studies of autologous cell transplantation using
reprogramming and rediﬀerentiation to a speciﬁc cell lineage. A
skin biopsy is taken from an individual marmoset, and ﬁbroblasts
from the biopsy are grown in culture. Reprogramming factors are
expressed in the cells; over a period of several weeks, clones of
cells arise that may be iPS cells. Clones are isolated and screened
to determine whether they are properly reprogrammed iPS cells; if
so, they are expanded and cryopreserved. Neuronal progenitor cells
(NPCs) are derived from these iPS cells via protocols described in
the text. If the NPCs pass stringent tests of diﬀerentiation potential
and safety, in the future they may be implanted into the CNS of the
same individual from which the cells were originally derived.
from the use of immunosuppressive drugs. They would, in
other words, be the “gold standard” for the best possible
results of therapy based on cell transplantation. While
allogeneic cells might produce an acceptable result for
the patient, autologous cell transplants would provide the
standard by which the results of allogeneic cells could be
judged.
Shortly after the discovery of iPS cells, the technology
was used in a tour-de-force study in which iPS cells were
derived from a strain of mice that model human sickle cell
anemia. The genetic defect was corrected in the iPS cells
and they were transplanted back into mice of the same
strain following diﬀerentiation to hematopoietic stem cells
[6]. The symptoms in the treated mice were substantially
ameliorated.Thiswastheﬁrstdemonstrationofthepotential
power of iPS cell-based therapy. As these cells were derived
from, and reintroduced into, mice of the same strain, they
are an example of the use of syngeneic cells, rather than
truly autologous cells. Subsequently, another study suggested
that syngeneic iPS cells and their cell progeny may, in fact,
elicit an immune response [7]. This unexpected ﬁnding
has not yet received a satisfactory explanation. At the date
of writing, the question of the immunogenicity of iPS
cells and derivatives has only been addressed in mice, and
not yet in more translationally relevant species, including
primates.
Would therapeutic approaches based on the use of autol-
ogous cells be worth the considerable eﬀorts of development
and implementation that would be required? The answer
at the moment is quite unknown. First, in the absence of
suitable translational models, or actual clinical trials of iPS
cell-based therapy, the advantages must remain theoretical.
We do not know how much better, or not, therapy based
on autologous cells would be in comparison to therapy
based on allogeneic cells. Possibly, autologous cells will prove
to be superior, but perhaps there will be little diﬀerence
from allogeneic cells. In some therapies, the need for a
very rapid treatment would preclude the use of autologous
cells. For example, in stroke, due to the need for immediate
treatment, “oﬀ-the-shelf” cells would be needed and iPS
cells are unlikely to be useful. However, understanding
whether immune-matched versus mismatched cells would
have an advantage in a stroke model would be of great
signiﬁcance.
Second, it is extremely hard to predict how easily-
implemented iPS cell-based therapy would eventually
become. When iPS cells were ﬁrst made from skin ﬁbroblasts
in 2006-2007, reprogramming was highly ineﬃcient and
laborious. Over the last 4 years, there has been astounding
progress in terms of better, simpler protocols and increases
in eﬃciency [8–11]. Given that there are no reasons to
think that the process should not continue to undergo
such improvement in eﬃciency, it is quite possible that the
creation of iPS cells from a patient’s cells would become
quite routine and inexpensive at some time in the future.
Similar dramatic improvements in eﬃciency and cost have
been seen in other biomedical technologies, for example,
DNA sequencing.
3. Importance of Nonhuman Primate Research
in Regenerative Medicine
Before it would be possible to consider applying autologous
cell therapy to human patients, the properties of iPS cells
must be thoroughly explored in suitable animal models, in
order to make sure that autologous cell therapy is both safe
and eﬀective. It has been generally recognized that clinically
relevant experiments should be performed in a nonhuman
primate (NHP) rather than a rodent. NHPs are thought be
ideal for such preclinical trials because of their relatedness
to humans and their similar physiology, particularly with
respect to the central nervous system. Long-term studies
of transplanted cell function (>3y e a r s )w i l lb ep o s s i b l ei n
NHPs, but are impossible in rodents.
Thus there is a clear path from basic to translational
studies in iPS cell-based regenerative medicine in NHPs. Of
the various NHPs that could be used, the marmoset has
several key advantages. The common marmoset (Callithrix
jacchus) has the advantage of smaller size, more rapid
breeding, and deﬁned housing conditions. In contrast to
humans,whereuncontrolledenvironmentandmanycomor-
bidities are confounding factors, marmosets can be housedStem Cells International 3
Table 1: Publications on nonhuman primate iPS cells.
Species Title of publication cDNAs used for reprogramming Origin of cDNAs
Rhesus macaque (Macaca
mulatta)
Generation of induced pluripotent stem
cells from adult rhesus monkey
ﬁbroblasts [24]
POU5F1, SOX2 KLF4 and MYC Rhesus
Common marmoset (Callithrix
jacchus)
Generation of induced pluripotent stem
cells from newborn marmoset skin
ﬁbroblasts [25]
POU5F1, SOX2 KLF4 and MYC Human
Common marmoset (Callithrix
jacchus)
Generating induced pluripotent stem
cells from common marmoset (Callithrix
jacchus) fetal liver cells using deﬁned
factors, including Lin28 [26]
POU5F1, SOX2, KLF4, MYC,
NANOG and LIN28 Human
Rhesus macaque (Macaca
mulatta)
Reprogramming Huntington monkey
skin cells into pluripotent stem cells [27] POU5F1, SOX2 and KLF4 Rhesus
Pigtailed macaque (Macaca
nemestrina)
Eﬃcient generation of nonhuman
primate induced pluripotent stem cells
[28]
POU5F1, SOX2 KLF4 and MYC Human
Cynomolgus monkey (Macaca
fascicularis)
Development of histocompatible primate
induced pluripotent stem cells for neural
transplantation [29]
POU5F1, SOX2 KLF4 and MYC Human
Rhesus macaque (Macaca
mulatta)
Generation of pancreatic
insulin-producing cells from rhesus
monkey induced pluripotent stem cells
[30]
POU5F1, SOX2 KLF4 and MYC Rhesus
Pigtailed macaque (Macaca
nemestrina)
Safeguarding nonhuman primate iPS
cells with suicide genes [31] POU5F1, SOX2 KLF4 and MYC Human
Drill (Mandrillus leucophaeus) Induced pluripotent stem cells from
highly endangered species [32] POU5F1, SOX2 KLF4 and MYC Human
Cynomolgus monkey (Macaca
fascicularis)
Induction of retinal pigment epithelial
cells from monkey iPS cells [33] POU5F1, SOX2 KLF4 and MYC Human
The table lists the publications (in order of publication, up to September 2011) that have reported the derivation and characterization of nonhuman primate
iPS cells. All used mixtures of retroviruses, carrying the indicated cDNAs.
in a deﬁned environment and have few known comorbidities
[12]. A variety of human diseases can potentially be modeled
inmarmosets[13–15].Achemical-inducedmodelofParkin-
son’s disease has also been developed in this species [16]
and a stroke model [17] has been developed. Histological
and MRI brain atlases are available [18]. The marmoset
genome has been completed [19], and the marmoset is the
ﬁrst and so far only primate to have transgenic models that
show germline transmission [20]. Although transgenics have
also been created in the rhesus macaque, they have not
passed the transgene to their oﬀspring [21]. A genetic model
of Parkinson’s disease by overexpression of α-synuclein has
been developed in the marmoset [20]. Finally, a spinal
cord injury model in the marmoset has been used in
tests of transplanted human neural stem cells for potential
therapeutic eﬀect [22, 23]. Our long-term goal is illustrated
in Figure 1.
4.ProgressinNHPiPSCellResearch
Despite the importance of NHPs in regenerative medicine,
there has yet been relatively little work on iPS cells derived
from NHPs, in comparison to the extent of work on iPS
cells derived from mice and humans. The ﬁrst NHP iPS cells
were derived from the rhesus macaque [24]. At the present
time (September 2011), iPS cells have been derived from
ﬁve NHP species (Table 1); three species of macaque (rhesus
macaque, pigtailed macaque, and cynomolgus monkey),
the common marmoset, and an endangered primate, the
drill [24–33]. Common features of all reports on NHP iPS
cells are: derivation by mixtures of retroviruses carrying
transcription factor cDNAs, principally POU5F1, SOX2,
KLF4, and MYC; maintenance of pluripotent characteristics
over long-term growth in culture; ability to diﬀerentiate into
cells and tissues of the three germ layers; a lack of malignant
properties, despite the ability to form benign teratomas in
immunodeﬁcient mice [24–33].
5.Marmoset iPSCells:A Model for Autologous
Cell Therapy
T h ee v e n t u a lg o a lo fo u rs t u d i e si st od e r i v ei P Sc e l l sf r o m
individual marmosets and implant the cells into the donor
animal, following the directed diﬀerentiation of the iPS
cells to speciﬁc cell lineages (Figure 1). Before such studies
are possible, extensive in vitro investigations and studies in
immunodeﬁcient mice are needed.4 Stem Cells International
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Figure 2:Retroviralreprogrammingvectordesignedtodeliverfour
reprogramming factors (Oct4, Sox2, Klf4, and c-Myc; OSKM) in a
single virus using “self-cleaving” peptides, which support eﬃcient
polycistronic expression from a single promoter [8]. In this version,
expression is driven by the 5  LTR. Additionally, loxP sites are
present just before and just after the OSKM coding region, enabling
excision of the vector from the genome of the reprogrammed cells.
This vector was constructed by replacing the internal promoter (P)
and eukaryotic selection marker of retroviral vector pLXSN by the
OSKM sequence from FUW-OSKM [8].
W ec h o s et od e r i v em a r m o s e ti P Sc e l l sf r o ms k i n
ﬁbroblasts because the ﬁbroblast has been the most widely
studied cell type for iPS cell generation, and because the
use of small skin biopsies as a source of starting material
is relevant to future clinical application of iPS cells and
their derivatives. In initial experiments, we used ﬁbroblasts
derived from newborn marmoset skin [25]. Retroviruses
encoding the human cDNAs for Oct4, Sox2, Klf4, and c-
Myc [2] were prepared in Plat-A cells and were concentrated
by Polybrene ﬂocculation [34]. Following the infection of
the cells with concentrated viruses, cultures were maintained
in normal ﬁbroblast growth conditions with the addition
of valproic acid [35]. After 14–21 days, small colonies of
altered morphology were noted in the conﬂuent ﬁbroblast
cultures. These colonies comprised small rapidly dividing
cells with high nuclear/cytoplasmic ratio and prominent
nucleoli. When cultures containing such colonies were ﬁxed
and stained for alkaline phosphatase activity, most of the
small colonies of altered morphology were found to be
positive for alkaline phosphatase, a marker of pluripotency
[36]. These colonies expanded rapidly, producing very dense
patches of small cells. These cells have the morphological
characteristics previously reported for human iPS cells [2].
Starting with a population of 4 × 105 marmoset ﬁbrob-
lasts, we obtained ∼100 colonies of cells with iPS cell-like
morphology. Colonies were isolated and expanded on feeder
layers.Ofthosecoloniesthatwereisolatedfromtheﬁbroblast
cultures, 30 showed sustained growth and were able to be
expanded to the point where they could be cryopreserved.
Of these, 8 were selected for further study. Karyotypes were
investigated by G banding and were found to be normal
(a)
(b)
Figure 3: Marmoset iPS cells growing in feeder-free culture. (a) An
iPS cell line derived by coinfection with four retroviruses (B8 cell
line[25]).Cellsaregrowingindeﬁnedxeno-freemedium(Pluriton,
Stemgent). (b) An iPS cell line derived by infection with a single
retrovirus, encoding the OSKM reprogramming factors, illustrated
in Figure 2.
[25]. Following the initial expansion of marmoset iPS cell
clones on feeder layers, we investigated if the cells could
be grown under feeder-free conditions. Cells were replated
on Matrigel-coated dishes in medium containing 20% fetal
bovine serum and 40% MEF-conditioned medium and
continued to grow rapidly. Cell populations were expanded
under these conditions for further studies.
MarmosetiPScellclonesexpressedpluripotencymarkers
at levels that were comparable to that in a human embryonic
stem cell line (I6) or exceeded that level [25]. In all 8
marmoset iPS cell clones, NANOG and SOX2 mRNA levels
were higher than those in I6 cells, and levels of OCT4 were
comparable to that of I6 cells. Levels of OCT4 mRNA were
>100-fold higher in iPS cell clones than in the ﬁbroblasts
used for reprogramming, and levels of NANOG and SOX2
were >50-fold higher. We assessed the relative levels of vector
and total mRNAs for OCT4 and SOX2, two of the factors
used for reprogramming. We used primer pairs speciﬁc
for reprogramming vectors (vector sequence 5  primer and
coding region 3  primer). Vector OCT4 mRNA was present
at 0.01% to 0.1% of that of total OCT4 mRNA, while vector
SOX2 mRNA was present at 0.1% to 1% of the total SOX2Stem Cells International 5
(a) (b) (c)
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Figure 4: Derivation of neural progenitor cells (NPCs) from marmoset iPS cells and diﬀerentiation of NPCs to mature neurons. The series
(a)–(c) shows the transition from undiﬀerentiated iPS cells (a), to a line of NPCs (b), to mature neurons (c) (100x phase-contrast images).
NPCs placed on a polylysine/laminin-coated glass surface stop dividing and form extensive axons and dendrites. Details of this further
maturation are shown in series (d)–(f) (400x diﬀerential interference contrast images). Note particularly the varicosities of diﬀerent sizes
indicated by arrows in (f). These are sites of accumulation of cellular organelles and are precursors to the formation of synapses [37]. Their
presence indicates the degree of maturity of these neurons.
mRNA. These ﬁndings indicate that the viral genomes are
appropriately silenced [38].
In order to assess the potential of marmoset iPS cell
clones to diﬀerentiate to cells of all three germ layers, cells
were transplanted into immunodeﬁcient mice (subcuta-
neous injection in 50% Matrigel: [39, 40]). Teratomas from
marmoset iPS cells contained a variety of tissue structures
representing derivatives of all three germ layers. Because it
has been reported that teratomas derived from incompletely
reprogrammed cells formed tissues of ectodermal and
mesodermal origin but not of endodermal origin [38]w e
performed histological studies of the development of mature
structures of endodermal origin; we observed endodermal
tissues, including simple columnar and pseudostratiﬁed
epithelia, epithelia with goblet cells, and exocrine glandular
structures [25]. Immunohistochemical studies were also
performed; ectodermal tissue (developing neural tissue) was
demonstrated by presence of βIII tubulin; mesodermal tissue
by smooth muscle actin; endodermal tissue by α-fetoprotein.
Subsequently, we investigated the potential of a poly-
cistronic vector for reprogramming (Figure 2). This retrovi-
ral vector has the features that (a) because expression of the
reprogramming factors is driven by the 5  LTR, expression is
silenced during reprogramming, if cells have been properly
reprogrammed [38]; (b) all factors are in one vector, thus
avoiding the need for very high eﬃciency infection; (c) as
a retroviral vector, only dividing cells are infected (this does
not detract from the value of this type of vector, as iPS cells
must arise from cells capable of cell division); (d) loxP sites
enable future excision of the coding region when required.
Marmoset iPS cells derived using this polycistronic retroviral
vector exhibited the same characteristics of iPS cell clones
derived by coinfection of the four factors. Therefore, cells
derivedbya1:1:1:1expressionofthefourreprogramming
factors have properties that are basically the same as those
derived by coinfection, in which the ratio of expression of
the four factors is not necessarily equal and almost certainly
varies from clone to clone.
Despite the advantages of such retroviral vectors, it is
likely that the use of integrating forms of viral vectors
for reprogramming will be made obsolete by nonviral
reprogrammingmethodsusingmodiﬁedmRNAormodiﬁed
proteins [9]. These methods avoid any genetic modiﬁcation
of the target cells during the reprogramming process.
Successful long-term expansion of marmoset iPS cells
is critical for any extensive studies of the properties of6 Stem Cells International
the cells. Although we determined feeder-free conditions for
growth of the cells, these conditions require fetal bovine
serum and medium conditioned by a suitable cell type,
such as mouse embryo ﬁbroblasts. More recently, we have
established that marmoset iPS cells can grow continuously
and over long periods in deﬁned medium without the
addition of serum or of medium conditioned by another
cell type. Several types of deﬁned media support long-term
marmoset iPS cell growth without loss of expression of
pluripotency genes such as NANOG and OCT4/POU5F1.
Both clones derived by coinfection and clones derived by
infectionwithapolycistronicvectormaybegrownindeﬁned
medium (Figure 3).
In summary, by the criteria of morphology, growth
requirements, expression of pluripotency factors, retroviral
silencing, and the ability to generate teratomas with tissues
of all three germ layers, we conclude that these lines of cells
represent bona ﬁde induced pluripotent stem cells.
6. Differentiation of Marmoset iPS Cells to
Neural Progenitor Cells
In subsequent work, we investigated the potential of mar-
moset iPS cell lines to diﬀerentiate in vitro to cells of
the neural lineage. Diﬀerentiation of iPS cells to neural
progenitor cells (NPCs) has been extensively employed as
a test of proper pluripotency; for example, this form of
directed diﬀerentiation was used in a recent set of tests
on a panel of well characterized human iPS cells [10, 11].
Protocols for NPC generation are of three general types:
stromal cell-derived inducing activity (SDIA), a relatively
poorly characterized mix of factors secreted by certain
mesenchymal cells, such as the PA6 cell line [2, 41, 42];
embryoid body (EB) formation, followed by plating of the
EBs on suitable surfaces in the presence of Neurobasal
medium [43, 44]; and induction using small molecules,
such as chemical inhibition of BMP/activin/nodal signaling
via SMADs [45]. We have used each of these methods in
marmoset iPS cells, and all of them produce NPC lines
(Figure 4).
7. Summary
In summary, iPS cells from NHPs have a unique importance
in preclinical research leading to the implementation of
regenerative medicine in human patients. We have derived
and characterized iPS cells from the marmoset, a small NHP
that can serve as a suitable model for autologous cell therapy
involving iPS cells. Future studies will test the principles of
autologous cell therapy in individual marmosets.
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